サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：二重特異性抗体市場：製品タイプ別、用途別、適応症別、国別、地域別- 産業分析、市場規模、市場シェア、2023-2030年予測
市場調査レポート
商品コード
1320179

二重特異性抗体市場：製品タイプ別、用途別、適応症別、国別、地域別- 産業分析、市場規模、市場シェア、2023-2030年予測

Bispecific Antibody Market with COVID-19 Impact Analysis, By Product Type, By Application, By Indication, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030

出版日
ページ情報
英文 258 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.96円
二重特異性抗体市場：製品タイプ別、用途別、適応症別、国別、地域別- 産業分析、市場規模、市場シェア、2023-2030年予測
出版日: 2023年07月01日
発行: AnalystView Market Insights
ページ情報: 英文 258 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

レポートのハイライト

二重特異性抗体の市場規模は2022年に6億3,090万米ドル、2023年から2030年にかけてCAGR 8.3％で拡大

二重特異性抗体市場-市場力学：

がんの世界の負担増と効果的な治療薬がないことが、二重特異性抗体市場の成長を促進すると予想されます。

がんは世界の健康上の大きな課題であり、その負担は増加の一途をたどっています。がんの治療やケアは進歩しているが、根治的な治療法の欠如は依然として懸念事項です。がん免疫療法への有望なアプローチのひとつが、二重特異性抗体の使用です。世界保健機関（WHO）によれば、がんは世界の死因のトップであり、2020年には1,000万人近くが死亡するといわれています。二重特異性抗体は、多数の抗原を同時に、あるいは逐次的に標的とすることができるという利点があり、化学療法、低分子化合物、チェックポイント阻害剤のような免疫調節薬と併用することができます。研究開発活動の増加は市場に成長機会をもたらす可能性があります。しかし、医薬品開発に伴う高コストが市場成長の妨げとなっています。

二重特異性抗体市場-主要インサイト：

  • 二重特異性抗体産業は、持続可能な成長に対する意識の高まりにより、著しい速度で成長すると予測される
  • 製品タイプ別では、がんが2022年に最大の市場シェアを示す
  • 適応症別では、2022年にはカツマキソマブが主要タイプに
  • 地域別では、北米が2022年に収益を上げる主要市場

二重特異性抗体市場-セグメンテーション分析：

二重特異性抗体の世界市場は、適応症、製品タイプ、用途、地域に基づいてセグメント化されます。

市場は適応症に基づいて3つのカテゴリーに分けられる：がん、炎症性・自己免疫疾患、その他。がんが市場を独占しています。二重特異性抗体は、がん細胞に対する身体の免疫反応を強化する可能性を持つ免疫治療薬として大きな可能性を示しています。二重特異性抗体は、がん細胞を特異的に標的としたり、免疫細胞をより効果的に認識してがん細胞と闘うように改変したりするために使用されます。

市場は製品タイプによって2つのカテゴリーに分けられる：ブリナツモマブ（Blinatumomab）、カツマキソマブ（Catumaxomab）、デュリゴツマブ（Duligotumab）、その他です。カツマキソマブは市場を独占しており、予測期間中もその優位性を維持すると思われます。カツマキソマブは、がん治療に使用されてきた二重特異性抗体の具体例です。カツマキソマブは、悪性腹水（がん細胞が腹腔内に蓄積して体液が貯留する病態）の治療薬として開発された三機能性抗体です。

市場は用途によって2つのカテゴリーに分けられる：病院、専門クリニック、その他です。病院はがん治療の最先端にあり、二重特異性抗体のような最先端の医薬品を提供する上で重要な役割を果たすことが多いです。がん治療や免疫療法に重点を置く専門クリニックも、二重特異性抗体の投与に関与している可能性があります。

二重特異性抗体市場-地理的洞察：

地理的には、この市場は北米、ラテンアメリカ、欧州、アジア太平洋、中東・アフリカの地域に広がっています。これらの地域は、ビジネスを展開する国によってさらに分けられます。北米は肺がん、前立腺がん、乳がん、子宮頸がんなど、がんが多いため、二重特異性抗体市場を独占しています。これらのがんは二重特異性抗体の潜在的な標的であり、この地域におけるこのような治療法の需要を牽引しています。米国国立がん研究所は、2020年には米国で180万6590人が新たにがんと診断され、60万6,520人ががんで死亡すると予測しています。さらに、欧州とアジア太平洋地域は、標的療法と個別化療法の需要の高まりと、新しい二重特異性抗体のフォーマットと技術の出現により、二重特異性抗体市場の需要が増加すると予測されています。

二重特異性抗体市場-競合情勢：

二重特異性抗体市場は非常に競争が激しく、各企業は市場シェアと薬事承認取得を目指しています。二重特異性抗体の開発は製薬業界やバイオテクノロジー業界から大きな関心を集めており、市場競争は激化しています。数多くの企業が研究開発に資金を提供し、様々ながんやその他の疾患に焦点を当てた新規の二重特異性抗体候補を創出しています。二重特異性抗体の有用性を支持する研究が増えるにつれ、様々な種類のがんに対するこれらの治療法の開発・利用に対する関心が高まっています。いくつかの製薬会社やバイオテクノロジー企業は、独自の二重特異性抗体志願者を生み出すための研究開発に投資しています。このため、効果的な二重特異性抗体療法を市場に投入しようと競争する企業が増加しています。各社は、二重特異性抗体の設計を最適化し、製造工程を改善し、効果を高めるための併用療法を模索することで、自社製品の差別化を図っています。例えば、AmgenとXencor, Inc.は最近、がん免疫療法と炎症領域における新規治療薬の開発と商業化を目的とした研究・ライセンス契約を締結したと発表しました。この共同研究は、Amgenのターゲット探索とタンパク質治療薬における能力と、XencorのXmAb二重特異性技術プラットフォームを融合させるものです。

目次

第1章 二重特異性抗体市場概要

  • 調査範囲
  • 市場推定年数

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 二重特異性抗体の主要な市場動向

  • 二重特異性抗体市場促進要因
  • 二重特異性抗体市場抑制要因
  • 二重特異性抗体市場機会
  • 二重特異性抗体市場の今後の動向

第4章 二重特異性抗体産業の調査

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しのマッピング
  • 規制枠組みの分析

第5章 二重特異性抗体市場：COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19以後の影響分析

第6章 二重特異性抗体市場情勢

  • 二重特異性抗体市場シェア分析、2022年
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 二重特異性抗体市場-製品タイプ別

  • 概要
    • 製品タイプ別のセグメントシェア分析
    • ブリナツモマブ
    • カツマキソマブ
    • デュリゴツマブ
    • その他

第8章 二重特異性抗体市場- 用途別

  • 概要
    • 用途別のセグメントシェア分析
    • 病院
    • 専門クリニック
    • その他

第9章 二重特異性抗体市場- 適応症別

  • 概要
    • 適応症別セグメントシェア分析
    • がん
    • 炎症性・自己免疫疾患
    • その他

第10章 二重特異性抗体市場-地域別

  • イントロダクション
  • 北米
    • 概要
    • 主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • 主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • 主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東とアフリカ
    • 概要
    • 主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析- 二重特異性抗体産業

  • 競合ダッシュボード
  • 企業プロファイル
    • Genmab
    • Merus
    • Chugai Pharmaceutical
    • Ablynx
    • Genentech
    • Jounce Therapeutics
    • Affimed Therapeutics
    • Eli Lilly
    • AstraZeneca（MedImmune）
    • Neovii Biotech
    • Pieris
    • Adimab
    • Immunomedics
    • Roche
    • Amgen
    • Sanofi
    • Emergent BioSolutions
    • NovImmune SA
    • Regeneron Pharmaceuticals
    • EMD Serono
    • OncoMed Pharmaceuticals
    • MacroGenicsC

第12章 アナリストの全方位展望

図表

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Bispecific Antibody Market: Product Type Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Product Type
  • TABLE Global Bispecific Antibody Market, by Product Type 2018-2030 (USD Million)
  • TABLE Bispecific Antibody Market: Application Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Application
  • TABLE Global Bispecific Antibody Market, by Application 2018-2030 (USD Million)
  • TABLE Bispecific Antibody Market: Indication Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Indication
  • TABLE Global Bispecific Antibody Market, by Indication 2018-2030 (USD Million)
  • TABLE Bispecific Antibody Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Bispecific Antibody Market, by Region 2018-2030 (USD Million)
  • TABLE North America Bispecific Antibody Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Bispecific Antibody Market, by Product Type, 2018-2030 (USD Million)
  • TABLE North America Bispecific Antibody Market, by Application, 2018-2030 (USD Million)
  • TABLE North America Bispecific Antibody Market, by Indication, 2018-2030 (USD Million)
  • TABLE Europe Bispecific Antibody Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Bispecific Antibody Market, by Product Type, 2018-2030 (USD Million)
  • TABLE Europe Bispecific Antibody Market, by Application, 2018-2030 (USD Million)
  • TABLE Europe Bispecific Antibody Market, by Indication, 2018-2030 (USD Million)
  • TABLE Asia Pacific Bispecific Antibody Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Bispecific Antibody Market, by Product Type, 2018-2030 (USD Million)
  • TABLE Asia Pacific Bispecific Antibody Market, by Application, 2018-2030 (USD Million)
  • TABLE Asia Pacific Bispecific Antibody Market, by Indication, 2018-2030 (USD Million)
  • TABLE Latin America Bispecific Antibody Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Bispecific Antibody Market, by Product Type, 2018-2030 (USD Million)
  • TABLE Latin America Bispecific Antibody Market, by Application, 2018-2030 (USD Million)
  • TABLE Latin America Bispecific Antibody Market, by Indication, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Bispecific Antibody Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Bispecific Antibody Market, by Product Type, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Bispecific Antibody Market, by Application, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Bispecific Antibody Market, by Indication, 2018-2030 (USD Million)
目次
Product Code: ANV1490

REPORT HIGHLIGHT

Bispecific Antibody Market size was valued at USD 630.9 Million in 2022, expanding at a CAGR of 8.3% from 2023 to 2030.

Bispecific antibodies aim to treat multi-layered, complex diseases by engaging two disease targets with one molecule. They are synthetic hybrid molecules having two separate binding domains that target two unique antigens, as opposed to natural antibodies, which have two targeting arms that attach to the same target antigen. Bispecific antibodies are typically not found in nature but are instead created using recombinant DNA techniques or cell fusion. By focusing on two distinct disease pathways, bispecific antibodies have the potential to increase therapeutic efficacy in the treatment of complicated human diseases.

Bispecific Antibody Market- Market Dynamics:

The rising global burden of cancer and the unavailability of effective curing drugs possess are expected to propel the growth of the Bispecific Antibody Market.

Cancer is a significant global health challenge, and its burden continues to rise. While advances in cancer treatment and care have been made, the lack of viable curative treatments remains a concern. One promising approach to cancer immunotherapy is the use of Bispecific Antibodies. According to the world health organization, Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. Bispecific antibodies have the benefit of being able to target numerous antigens simultaneously and sequentially, and they can be employed in conjunction with chemotherapy, small compounds, and immunomodulatory medicines like checkpoint inhibitors. An increase in the number of research and development activities can provide growth opportunities for the market. However, the High cost associated with drug development hampers the market growth.

Bispecific Antibody Market- Key Insights:

  • As per the analysis shared by our research analyst, the global Bispecific Antibody market is estimated to grow annually at a CAGR of around 8.3% over the forecast period (2023-2030)
  • The Bispecific Antibody industry is projected to grow at a significant rate due to the growing awareness of sustainable growth
  • Based on Product Type segmentation, Cancer was predicted to show maximum market share in the year 2022
  • Based on Indication segmentation, Catumaxomab was the leading type in 2022
  • On the basis of region, North America was the leading revenue generator in 2022

Bispecific Antibody Market- Segmentation Analysis:

The Global Bispecific Antibody Market is segmented on the basis of Indication, Product Type, Application, and Region.

The market is divided into three categories based on Indication: Cancer, Inflammatory & Autoimmune Disorders, and Others. Cancer dominates the market. Bispecific antibodies have shown tremendous potential as immunotherapeutic medicines with the potential to enhance the body's immune response against cancer cells. They can be employed to specifically target cancer cells or modify immune cells to more effectively recognize and battle cancer cells.

The market is divided into two categories based on Product Type: Blinatumomab, Catumaxomab, Duligotumab, and Others. Catumaxomab dominates the market and is likely to maintain its dominance during the forecast period. Catumaxomab is a specific example of a bispecific antibody that has been used in cancer treatment. It is a trifunctional antibody that was developed for the treatment of malignant ascites, a condition where cancerous cells accumulate in the abdominal cavity and lead to fluid buildup.

The market is divided into two categories based on application: Hospitals, Specialty Clinics, and Others. Hospitals are on the cutting edge of cancer care and frequently play a crucial part in delivering cutting-edge medicines like bispecific antibodies. Specialty clinics that focus on cancer care or immunotherapy may also be involved in administering bispecific antibodies.

Bispecific Antibody Market- Geographical Insights:

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America dominates the Bispecific Antibody market due to the highest numbers of several cancers such as lung cancer, prostate cancer, breast cancer, and cervical cancer. These cancers are potential targets for bi-specific antibodies, driving the demand for such therapies in the region. National cancer institute predicted that in 2020, an estimated 1,806,590 new cases of cancer will be diagnosed in the United States and 606,520 people will die from the disease. Furthermore, Europe and Asia Pacific are projected to demand for Bispecific Antibody Market, due to the growing demand for targeted and personalized therapies and the emergence of novel bispecific antibody formats and technologies.

Bispecific Antibody Market- Competitive Landscape:

Bispecific antibody markets are highly competitive, with businesses aiming for market share and regulatory approvals for their goods. Bispecific antibody development has attracted significant interest from the pharmaceutical and biotechnology industries, raising market competition. Numerous companies have been funding research and development to create novel bispecific antibody candidates that focus on various cancers and other diseases. As more research supports the benefits of Bispecific antibodies, there is a growing interest in developing and utilizing these therapies for various types of cancer. Several pharmaceutical companies and biotechnology firms are investing in research and development to create their own Bispecific antibody applicants. This has led to an increase in the number of companies competing to bring effective Bispecific Antibody therapies to the market. Companies are striving to differentiate their products by optimizing the design of Bispecific Antibody, improving manufacturing processes, and exploring combination therapies to enhance their effectiveness. For Instance, Amgen and Xencor, Inc. announced nowadays that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation. The research collaboration brings together Amgen's capabilities in target discovery and protein therapeutics with Xencor's XmAb bispecific technology platform.

Recent Developments:

Dec. 19, 2022, Biogen Inc. announced that it has reached an agreement with Genentech, a member of the Roche Group, related to the commercialization and sharing of economics for glofitamab. Under the terms of the agreement, Biogen will have no payment obligations and will receive tiered royalties on potential net sales of glofitamab within the United States as part of the company's long-standing collaboration on antibodies targeting CD20.

Key features of the study:

  • This proposed research study on the Bispecific Antibody market provides market size (US$ Million), compound annual growth rate (CAGR %), and forecast estimation (2023-2030), considering 2022 as the base year
  • The report provides the client the latest up-to-date and trending insights about the Bispecific Antibody market.
  • The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Bispecific Antibody market
  • The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Bispecific Antibody market
  • Impact of COVID-19 on Bispecific Antibody market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Bispecific Antibody market post-COVID will also be covered.
  • In order to give the users of this report a comprehensive view on the Bispecific Antibody market, we have also included competitive landscape and key innovator analysis for the Bispecific Antibody market.
  • The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
  • The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Bispecific Antibody market.
  • In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
  • The global Bispecific Antibody market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BISPECIFIC ANTIBODY MARKET KEY PLAYERS

  • Genmab
  • Merus
  • Chugai Pharmaceutical
  • Ablynx
  • Genentech
  • Jounce Therapeutics
  • Affimed Therapeutics
  • Eli Lilly
  • AstraZeneca (MedImmune)
  • Neovii Biotech
  • Pieris
  • Adimab
  • Immunomedics
  • Roche
  • Amgen
  • Sanofi
  • Emergent BioSolutions
  • NovImmune SA
  • Regeneron Pharmaceuticals
  • EMD Serono
  • OncoMed Pharmaceuticals
  • MacroGenicsC

GLOBAL BISPECIFIC ANTIBODY MARKET, BY INDICATION

  • Cancer
  • Inflammatory & Autoimmune Disorder
  • Others

GLOBAL BISPECIFIC ANTIBODY MARKET, BY PRODUCT TYPE

  • Blinatumomab
  • Catumaxomab
  • Duligotumab
  • Others

GLOBAL BISPECIFIC ANTIBODY MARKET, BY END-USER

  • Hospital
  • Specialty Clinics
  • Others

GLOBAL BISPECIFIC ANTIBODY MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Bispecific Antibody Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Bispecific Antibody Market Snippet by Product Type
    • 2.1.2. Bispecific Antibody Market Snippet by Application
    • 2.1.3. Bispecific Antibody Market Snippet by Indication
    • 2.1.4. Bispecific Antibody Market Snippet by Country
    • 2.1.5. Bispecific Antibody Market Snippet by Region
  • 2.2. Competitive Insights

3. Bispecific Antibody Key Market Trends

  • 3.1. Bispecific Antibody Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Bispecific Antibody Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Bispecific Antibody Market Opportunities
  • 3.4. Bispecific Antibody Market Future Trends

4. Bispecific Antibody Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Bispecific Antibody Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Bispecific Antibody Market Landscape

  • 6.1. Bispecific Antibody Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Bispecific Antibody Market - By Product Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product Type, 2022 & 2030 (%)
    • 7.1.2. Blinatumomab
    • 7.1.3. Catumaxomab
    • 7.1.4. Duligotumab
    • 7.1.5. Others

8. Bispecific Antibody Market - By Application

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Application, 2022 & 2030 (%)
    • 8.1.2. Hospital
    • 8.1.3. Specialty Clinics
    • 8.1.4. Others

9. Bispecific Antibody Market - By Indication

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Indication, 2022 & 2030 (%)
    • 9.1.2. Cancer
    • 9.1.3. Inflammatory & Autoimmune Disorder
    • 9.1.4. Others

10. Bispecific Antibody Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Bispecific Antibody Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Bispecific Antibody Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Bispecific Antibody Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Bispecific Antibody Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Bispecific Antibody Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Product Type, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Bispecific Antibody Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Genmab
    • 11.2.2. Merus
    • 11.2.3. Chugai Pharmaceutical
    • 11.2.4. Ablynx
    • 11.2.5. Genentech
    • 11.2.6. Jounce Therapeutics
    • 11.2.7. Affimed Therapeutics
    • 11.2.8. Eli Lilly
    • 11.2.9. AstraZeneca (MedImmune)
    • 11.2.10. Neovii Biotech
    • 11.2.11. Pieris
    • 11.2.12. Adimab
    • 11.2.13. Immunomedics
    • 11.2.14. Roche
    • 11.2.15. Amgen
    • 11.2.16. Sanofi
    • 11.2.17. Emergent BioSolutions
    • 11.2.18. NovImmune SA
    • 11.2.19. Regeneron Pharmaceuticals
    • 11.2.20. EMD Serono
    • 11.2.21. OncoMed Pharmaceuticals
    • 11.2.22. MacroGenicsC

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us